InvestorsHub Logo
Followers 32
Posts 2200
Boards Moderated 0
Alias Born 09/01/2020

Re: flipper44 post# 607169

Thursday, 07/06/2023 1:59:35 PM

Thursday, July 06, 2023 1:59:35 PM

Post# of 701168
As I have been saying, there will be no application submission/acceptance news in Q3. Only dangling of carrots (from supporters).

Per my earlier post, one of these excuses will be hyped up as we approach mid to late Q3 (in an attempt to build lofty expectations and attract more buying from retail).

1) The focus has shifted to FDA now? UK not number one priority anymore. So need more time to line up CRL and other million BLA pages?

2) Now applying strategically via Project Orbis. All RAs at once. Need extra months.

3) Flaskworks certification given off label demand considerations!

4) Tissue agnostic approvals.

5) No MAA acceptance PR. Need to wait until final MHRA approval (in 2024?) for the big reveal.

6) Rolling review already in the works. Approval(s) can come anytime.

Ultimately, they will PR MAA acceptance news but it won’t be in Q3. Highly unlikely in Q4 either. We could potentially be under 40 cents before that news ever comes. It will again be very disappointing for most folks in terms of the impact on SP.

The report in August will also be revealing in terms of the specials revenue and the financing (including C shares). I expect we will be under 50 cents before that August report comes out as some of the folks connected to the management sell a bit of their position to buy back at a lower price point later in the year. These guys know regulatory application submissions are still some months away!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News